Remifentanil
Remifentanil is a potent, ultra-short-acting synthetic opioid analgesic used to provide pain relief during general anaesthesia and monitored anaesthesia care. It works by activating mu-opioid receptors in the central nervous system, reducing the perception of pain and producing dose-dependent sedation. It is administered by continuous intravenous infusion in a hospital or operating-room setting, with dosing carefully adjusted by trained anaesthesia professionals. Common adverse effects include nausea, vomiting, muscle rigidity, itching, and low blood pressure. Serious risks include respiratory depression, apnoea, bradycardia, and potentially life-threatening muscle rigidity, particularly with rapid or high-dose administration. Continuous monitoring of breathing, oxygenation, and cardiovascular function is essential, and appropriate airway and resuscitation support must be available.
Remifentanil was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Remifentanil, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Remifentanil from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Remifentanil, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
